Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Parallel, Single-dose Phase I Clinical Study on the Pharmacokinetics and Safety of TQD3524 for Injection in Renal Impairment Subjects

NCT06522945 is registered in ClinicalTrials.gov with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. as lead sponsor.

NCT NCT06522945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06522945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Parallel, Single-dose Phase I Clinical Study on the Pharmacokinetics and Safety of TQD3524 for Injection in Renal Impairment Subjects
Lead sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
July 24, 2024
Completion date
December 18, 2025
Enrollment
48 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multi-resistant gram-negative bacteria cause infection